The circulating tumour cell (CTC) capture technology by NetScientific PLC'S (LON:NSCI) investee company Vortex Biosciences has been further endorsed in two research papers.
As reported last month, the firm has begun the commercial launch of its VTX1 Liquid Biopsy System, which offers a breakthrough in early cancer detection.
The recent study published in 'Nature Communications' describes the use of Vortex technology to capture CTCs in a preliminary step to performing a single-CTC Western blot test by researchers at three US universities.
READ - NetScientific hails commercial launch of breakthrough cancer detection device
WATCH - NetScientific boss proud of cancer diagnostic tool's achievements
Such a test is often used as a follow-up to confirm the presence of an antibody to help diagnosis.
The study showed the Vortex test provided a unique targeted proteomics approach to understanding CTC cancer biology.
Meanwhile, data to be presented at the American Association for Cancer Research between 1 and 5 April will demonstrate the ability of Vortex's technology to rapidly collect highly enriched populations of CTCs, undamaged by labels or reagents, for colorectal cancer, non-small cell lung cancer (NSCLC), breast cancer and drug testing research.
François R. Martelet, NetScientific's chief executive and chairman of Vortex Biosciences, said: "We are proud to see Vortex progress its VTX-1 system to demonstrate its simplicity and performance representing the next step in CTC isolation, whilst enabling cancer researchers to directly access the cancer biology of the patient.
"We believe that CTC technology will increasingly feature in ground-breaking work to enhance our understanding of cancer.
AIM-listed Netscientific owns 95% of Vortex having invested just over £13mln in the business.